Natural selection of tumor variants in the generation of “tumor escape” phenotypes

Khong, Hung T., Restifo, Nicholas P.·2002·Nature Immunology
DOI 10.1038/ni1102-999

Cited by (998)

Items 101–200 of 998

  1. Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
    Arnav Mehta, Yeon Joo Kim, Lídia Robert, Jennifer Tsoi, Begoña Comı́n-Anduix, Beata Berent-Maoz, Alistair J. Cochran, James S. Economou, Paul C. Tumeh, Cristina Puig-Saus et al. · 2018 · Cancer Discovery
  2. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression
    Murrium Ahmad, RobertC. Rees, SelmanA. Ali · 2004 · Cancer Immunology Immunotherapy
  3. Cancer Immunotherapy Based on Killing of Salmonella -Infected Tumor Cells
    Francesca Avogadri, Chiara Martinoli, Liljana Petrovska, Claudia Chiodoni, Pietro Transidico, Vincenzo Bronte, Renato Longhi, Mario P. Colombo, Gordon Dougan, María Rescigno · 2005 · Cancer Research
  4. IFN Unresponsiveness in LNCaP Cells Due to the Lack of JAK1 Gene Expression
    Gavin P. Dunn, Kathleen C. F. Sheehan, Lloyd J. Old, Robert D. Schreiber · 2005 · Cancer Research
  5. Tumor Evasion from T Cell Surveillance
    Katrin Töpfer, Stefanie Kempe, Nadja Müller, Marc Schmitz, Michael Philipp Bachmann, Marc Cartellieri, Gabriele Schackert, Achim Temme · 2011 · BioMed Research International
  6. Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth
    Alyssa K. Kosmides, John-William Sidhom, Andrew K. Fraser, Catherine Ami Bessell, Jonathan P. Schneck · 2017 · ACS Nano
  7. Immune Evasion by Murine Melanoma Mediated through CC Chemokine Receptor-10
    Takashi Murakami, Adela Rambi Cardones, Steven Eric Finkelstein, Nicholas P. Restifo, Brenda A. Klaunberg, Frank Oliver Nestle, S. Sianna Castillo, Phillip A. Dennis, Samuel T. Hwang · 2003 · The Journal of Experimental Medicine
  8. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients
    Eliane C.M. Zeestraten, Marlies S. Reimers, S. Saadatmand, J-W T Dekker, Gerrit‐Jan Liefers, Peter J. van den Elsen, C.J.H. van de Velde, Peter J.K. Kuppen · 2013 · British Journal of Cancer
  9. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?
    Michael R. Shurin, Galina V. Shurin, Anna E Lokshin, Zoya R. Yurkovetsky, Dmitry W. Gutkin, Gurkamal S. Chatta, Hua Zhong, Baohui Han, Robert Louis Ferris · 2006 · Cancer and Metastasis Reviews
  10. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants
    Thorbald van Hall, Elisabeth Z. Wolpert, Peter A. van Veelen, Sandra Laban, Michael van der Veer, Marjet Roseboom, Sandra A. Bres-Vloemans, Per Grufman, Arnoud de Ru, Hugo D. Meiring et al. · 2006 · Nature Medicine
  11. Heme oxygenase‐1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3‐dioxygenase
    Marcelo Hill, Victoria Pereira, Christine Chauveau, Rachid Zagani, Séverine Remy, Laurent Tesson, Daniel Mazal, Luis Ubillos, Régis Brion, Kashif Ashgar et al. · 2005 · The FASEB Journal
  12. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
    Sherille D. Bradley, Zeming Chen, Brenda Melendez, Amjad H. Talukder, Jahan S. Khalili, Tania Rodríguez-Cruz, Shujuan Liu, Mayra Whittington, Wanleng Deng, Fenge Li et al. · 2015 · Cancer Immunology Research
  13. IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting
    Kazuyoshi Takeda, M. NAKAYAMA, Yoshihiro Hayakawa, Yuko Kojima, Hiroaki Ikeda, Naoko Imai, Kouetsu Ogasawara, Ko Okumura, David Morgan Thomas, Mark John Smyth · 2017 · Nature Communications
  14. Supernatural T cells: genetic modification of T cells for cancer therapy
    Michael H. Kershaw, Michele W.L. Teng, Mark John Smyth, Phillip Kevin Darcy · 2005 · Nature reviews. Immunology
  15. Shedding Light on Immunotherapy for Cancer
    Steven A. Rosenberg · 2004 · New England Journal of Medicine
  16. Adoptive Transfer of Tumor-Reactive Transforming Growth Factor-β–Insensitive CD8+ T Cells: Eradication of Autologous Mouse Prostate Cancer
    Qiang Zhang, Ximing J. Yang, Michael Pins, Borko Javonovic, Timothy Michael Kuzel, Seong‐Jin Kim, Luk Van Parijs, Norman M. Greenberg, Victoria Liu, Yinglu Guo et al. · 2005 · Cancer Research
  17. MHC Class I Antigens and Immune Surveillance in Transformed Cells
    Aptsiauri, Natalia, Cabrera, Teresa, Garcia‐Lora, Angel, Lopez‐Nevot, Miguel Angel, Ruiz‐Cabello, Francisco, Garrido, Federico · 2007 · International Review of Cytology
  18. Effective immunotherapy against cancer
    Karl‐Johan Malmberg · 2004 · Cancer Immunology Immunotherapy
  19. Immunogenic ferroptosis and where to find it?
    Robin Demuynck, Iuliia Efimova, Faye Naessens, Dmitri V. Krysko · 2021 · Journal for ImmunoTherapy of Cancer
  20. Selective infiltration of CCR5 + CXCR3 + T lymphocytes in human colorectal carcinoma
    Hiroaki Musha, Haruo Ohtani, Takayuki Mizoi, Makoto Kinouchi, Takashi Nakayama, Kennichi Shiiba, 菊雄 宮川, Hiroshi Nagura, Osamu Yoshie, Iwao Sasaki · 2005 · International Journal of Cancer
  21. Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
    Özlem Türeci, Mathias Vormehr, Mustafa Diken, Sebastian Kreiter, Christoph Huber, Uğur Şahin · 2016 · Clinical Cancer Research
  22. De novoInduction of a Cancer/Testis Antigen by 5-Aza-2′-Deoxycytidine Augments Adoptive Immunotherapy in a Murine Tumor Model
    Zong Sheng Guo, Julie A. Hong, Kari R. Irvine, G. Aaron Chen, Paul J. Spiess, Yang Liu, Gang Zeng, John R. Wunderlich, Dao M. Nguyen, Nicholas P. Restifo et al. · 2006 · Cancer Research
  23. Next-Generation Cancer Immunotherapy Targeting Glypican-3
    Yasuhiro Shimizu, Toshihiro Suzuki, Toshiaki Yoshikawa, Itaru Endo, Tetsuya Nakatsura · 2019 · Frontiers in Oncology
  24. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis
    Randy Christopher Bowen, Nancy Ann B. Little, Joshua R. Harmer, Junjie Ma, Luke G. Mirabelli, Kyle D. Roller, A. Mackay Breivik, Emily A. Signor, Alec B. Miller, Hung T. Khong · 2017 · Oncotarget
  25. Tumor STAT1 Transcription Factor Activity Enhances Breast Tumor Growth and Immune Suppression Mediated by Myeloid-derived Suppressor Cells
    Laura M. Hix, John Karavitis, Mohammad Wasim Khan, Yihui H. Shi, Khashayarsha Khazaie, Ming Zhang · 2013 · Journal of Biological Chemistry
  26. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells
    Susanne Strand, Petra Vollmer, Lothar van den Abeelen, Daniela Gottfried, Vijay Alla, Hans Heid, Jurgen H. E. Kuball, Matthias Theobald, Peter R. Galle, Dennis J. Strand · 2004 · Oncogene
  27. Role of Altered Expression of HLA Class I Molecules in Cancer Progression
    Natalia Aptsiauri, Teresa Cabrera, Rosa Méndez, Angel Garcia-Lor, Francisco Ruiz‐Cabello, Federico Garrido · 2007 · Advances in experimental medicine and biology
  28. Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1
    Gang Xiao, Anqi Deng, Haifeng Liu, Gaoxiang Ge, Xiaolong Liu · 2012 · Proceedings of the National Academy of Sciences
  29. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis
    Gianpietro Dotti, Barbara Savoldo, Martin A. Pulè, Karin C. M. Straathof, Ettore Biagi, Eric S. Yvon, Stéphane Vigouroux, Malcolm K. Brenner, Cliona M. Rooney · 2005 · Blood
  30. Immune Response Against Dying Tumor Cells
    Laurence Zitvogel, Noëlia Casares, Marie O. Péquignot, Nathalie Chaput, Matthew L. Albert, Guido Kroemer · 2004 · Advances in immunology
  31. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy
    Rafael Carretero, José María Romero, Francisco Ruiz‐Cabello, Isabel Maleno, Felix Rodriguez, Francisco M. Camacho, Luís Miguel Real, Federico Garrido, Teresa Cabrera · 2008 · Immunogenetics
  32. The cancer biology of whole-chromosome instability
    Pascal H. G. Duijf, Robert Benezra · 2013 · Oncogene
  33. NKT Cell Networks in the Regulation of Tumor Immunity
    Faith C. Robertson, Jay A. Berzofsky, Masaki Terabe · 2014 · Frontiers in Immunology
  34. Tumour Cell Heterogeneity
    Laura J. Gay, Ann‐Marie Baker, Trevor A. Graham · 2016 · F1000Research
  35. Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells
    Yong Zhong, Kaopeng Guan, Sujuan Guo, Chunxia Zhou, Dongmei Wang, Wenbo Ma, Youhui Zhang, Changling Li, Shuren Zhang · 2010 · Cancer Letters
  36. Toll-like Receptors in Tumor Immunotherapy
    Chrystal Mary Paulos, Andrew Kaiser, Claudia Wrzesinski, Christian S. Hinrichs, Lydie Cassard, Andrea Boni, Pawel J. Muranski, Luis A Sanchez-Perez, Douglas C. Palmer, Zhiya Yu et al. · 2007 · Clinical Cancer Research
  37. Dynamic response of cancer under the influence of immunological activity and therapy
    Harold P. de Vladar, Jorge A. González · 2004 · Journal of Theoretical Biology
  38. Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity
    Guangchuan Wang, Ryan Dz-Wei Chow, Zhigang Bai, Lvyun Zhu, Youssef Errami, Xiaoyun Dai, Matthew B. Dong, Lupeng Ye, Xiaoya Zhang, Paul A. Renauer et al. · 2019 · Nature Immunology
  39. Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion
    Daniel J. Powell, Mark E. Dudley, Katherine Hogan, John R. Wunderlich, Steven A. Rosenberg · 2006 · The Journal of Immunology
  40. Immune evasion in acute myeloid leukemia: current concepts and future directions
    Ryan M. Teague, Justin Paul Kline · 2013 · Journal for ImmunoTherapy of Cancer
  41. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis
    C Zheng, L Li, Markus Haak, Benedikt Brors, Oliver Frank, Michelle Giehl, Alice Charlotte Fabarius, Michael C. Schatz, Andreas Weisser, Christian Lorentz et al. · 2006 · Leukemia
  42. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
    Motoki Miyazawa, R. Ohsawa, Takuya Tsunoda, Seiko Hirono, Manabu Kawai, Masaji Tani, Yusuke Nakamura, Hiroki Yamaue · 2009 · Cancer Science
  43. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells
    Wei‐Zen Wei, Gerald P. Morris, Yi-chi M. Kong · 2003 · Cancer Immunology Immunotherapy
  44. Epigenetic regulation of immune escape genes in cancer
    Thomas B. Tomasi, William J. Magner, Anm Nazmul H. Khan · 2006 · Cancer Immunology Immunotherapy
  45. Classical and Nonclassical HLA Class I Antigen and NK Cell–Activating Ligand Changes in Malignant Cells: Current Challenges and Future Directions
    Chien‐Chung Chang, Michael R. Campoli, Soldano Ferrone · 2005 · Advances in cancer research
  46. A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer
    Tomoko Saito, Atsushi Niida, Ryutaro Uchi, Hidenari Hirata, Hisateru Komatsu, Shotaro Sakimura, Shuto Hayashi, Sho Nambara, Yosuke Kuroda, Shuhei Ito et al. · 2018 · Nature Communications
  47. A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+T cell receptor repertoire clonality
    Wei Zhu, Claire Germain, Zheng Liu, Yinong Sebastian, Priyanka Devi-Marulkar, Samantha Knockaert, Philip Z. Brohawn, Kim P. Lehmann, Diane Damotte, Pierre Validire et al. · 2015 · OncoImmunology
  48. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer
    Varun Sasidharan Nair, Salman M. Toor, Rowaida Ziad Taha, Hibah Shaath, Eyad Elkord · 2018 · Clinical Epigenetics
  49. Engagement of TLR3, TLR7, and NKG2D Regulate IFN-γ Secretion but Not NKG2D-Mediated Cytotoxicity by Human NK Cells Stimulated with Suboptimal Doses of IL-12
    Marı́a Victoria Girart, Mercedes Beatriz Fuertes, Carolina I. Domaica, Lucas Ezequiel Rossi, Norberto W. Zwirner · 2007 · The Journal of Immunology
  50. Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation
    Itzel Bustos Villalobos, Yoshiyuki Takahashi, Yoshiki Akatsuka, Hideki Muramatsu, Nobuhiro Nishio, Asahito Hama, Hiroshi Yagasaki, Hiroh Saji, Motohiro Kato, Seishi Ogawa et al. · 2010 · Blood
  51. Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction
    Douglas C. Palmer, Sanjeeve Balasubramaniam, Ken‐ichi Hanada, Claudia Wrzesinski, Zhiya Yu, Shahram S. Farid, Marc Robert Theoret, Leroy N. Hwang, Christopher Austin Klebanoff, Luca Gattinoni et al. · 2004 · The Journal of Immunology
  52. Immune escape mechanisms of intraocular tumors
    Jérry Y. Niederkorn · 2009 · Progress in Retinal and Eye Research
  53. Identification of T-cell epitopes for cancer immunotherapy
    Jan H. Kessler, Cornelis J.M. Melief · 2007 · Leukemia
  54. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma
    Sattva Swarup Neelapu, Larry W. Kwak, Carol B. Kobrin, Craig W. Reynolds, John Edward Janik, Kieron M. Dunleavy, Therese White, Linda K. Harvey, Robin Pennington, Maryalice Stetler‐Stevenson et al. · 2005 · Nature Medicine
  55. An error catastrophe in cancer?
    Ricard V. Solé, Thomas S. Deisboeck · 2004 · Journal of Theoretical Biology
  56. Immunobiology of Merkel Cell Carcinoma: Implications for Immunotherapy of a Polyomavirus-Associated Cancer
    Shailender Bhatia, Olga K. Afanasiev, Paul Nghiem · 2011 · Current Oncology Reports
  57. Tumor Microenvironment Promotes Cancer Progression, Metastasis, and Therapeutic Resistance
    Shian‐Ying Sung, Chia‐Ling Hsieh, Daqing Wu, Leland W.K. Chung, Peter A.S. Johnstone · 2007 · Current Problems in Cancer
  58. CD1d-Expressing Breast Cancer Cells Modulate NKT Cell-Mediated Antitumor Immunity in a Murine Model of Breast Cancer Metastasis
    Laura M. Hix, Yihui H. Shi, Randy Richard Brutkiewicz, Paul L. Stein, Chyung-Ru Wang, Ming Zhang · 2011 · PLoS ONE
  59. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells
    Lili Yang, David Baltimore · 2005 · Proceedings of the National Academy of Sciences
  60. In Vivo Autofluorescence Imaging of Tumor Heterogeneity in Response to Treatment
    Amy T. Shah, Kirsten E. Diggins, Alex J. Walsh, Jonathan Michael Irish, Melissa C. Skala · 2015 · Neoplasia
  61. Intracellular Retention of the NKG2D Ligand MHC Class I Chain-Related Gene A in Human Melanomas Confers Immune Privilege and Prevents NK Cell-Mediated Cytotoxicity
    Mercedes Beatriz Fuertes, Marı́a Victoria Girart, Luciana Lorena Molinero, Carolina I. Domaica, Lucas Ezequiel Rossi, María Marcela Barrio, José Mordoh, Gabriel A. Rabinovich, Norberto W. Zwirner · 2008 · The Journal of Immunology
  62. Modeling Cell Communication in Cancer With Organoids: Making the Complex Simple
    Elena Fiorini, Lisa Veghini, Vincenzo Corbo · 2020 · Frontiers in Cell and Developmental Biology
  63. Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape
    Tania Sarkar, Subhanki Dhar, G. Sa · 2021 · Current Research in Immunology
  64. HLA-G and IL-10 expression in human cancer—different stories with the same message
    Mirjana Urosevic, Reinhard Dummer · 2003 · Seminars in Cancer Biology
  65. Adjuvant-Mediated Tumor Regression and Tumor-Specific Cytotoxic Response Are Impaired in MyD88-Deficient Mice
    Takashi Akazawa, Hisayo Masuda, Yoshiko Saeki, Misako Matsumoto, Kiyoshi Takeda, Kunio Tsujimura, Kiyotaka Kuzushima, Toshitada Takahashi, Ichiro Azuma, Shizuo Akira et al. · 2004 · Cancer Research
  66. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes
    Xue‐Feng Bai, Jinqing Liu, Li Ou, Pan Zheng, Yang Liu · 2003 · Journal of Clinical Investigation
  67. Dynamic response of cancer under the influence of immunological activity and therapy
    Harold P. de Vladar, Jorge A. González · 2006 · Journal of Theoretical Biology
  68. Comparative Analysis of Regulatory and Effector T Cells in Progressively Growing versus Rejecting Tumors of Similar Origins
    Jack D. Bui, Ravindra Uppaluri, Chyi‐Song Hsieh, Robert D. Schreiber · 2006 · Cancer Research
  69. MicroRNAs, Regulatory Messengers Inside and Outside Cancer Cells
    Simone Anfossi, Xiao Fu, Rahul Nagvekar, George A. Călin · 2018 · Advances in experimental medicine and biology
  70. CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory
    Lorenzo Mortara, Patrizia Castellani, Raffaella Meazza, Giovanna Tosi, Andrea De Lerma Barbaro, Francesco A. Procopio, Alberto Comes, Luciano Zardi, Silvano Ferrini, Roberto Sergio Accolla · 2006 · Clinical Cancer Research
  71. Immunotherapy for colorectal cancer: where are we heading?
    Debora Basile, Silvio Ken Garattini, Marta Bonotto, Elena Ongaro, Mariaelena Casagrande, Monica Cattaneo, Valentina Fanotto, Elisa De Carlo, Fotios Loupakis, Federica Urbano et al. · 2017 · Expert Opinion on Biological Therapy
  72. The evolutionary origin of genetic instability in cancer development
    Jarle Breivik · 2004 · Seminars in Cancer Biology
  73. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy
    Qiujun Qiu, Cong Li, Yanzhi Song, Tao Shi, Xiang Luo, Hongxia Zhang, Ling Hu, Xinyang Yan, Huangliang Zheng, Mengyang Liu et al. · 2019 · Acta Biomaterialia
  74. Tumor Microenvironment and Immune Escape
    Soldano Ferrone, Theresa L. Whiteside · 2007 · Surgical Oncology Clinics of North America
  75. The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance
    Hassan Dianat‐Moghadam, Mehdi Azizi, Zahra Eslami‐S, Luis Enrique Cortés‐Hernández, Maryam Heidarifard, Mohammad Nouri, Catherine Alix‐Panabières · 2020 · Cancers
  76. Mimotope vaccination – from allergy to cancer
    Regina Knittelfelder, Angelika Beate Riemer, Erika Jensen‐Jarolim · 2009 · Expert Opinion on Biological Therapy
  77. Recombinant Tumor-Associated MUC1 Glycoprotein Impairs the Differentiation and Function of Dendritic Cells
    Aurelia Rughetti, Ilenia Pellicciotta, Mauro Biffoni, Malin Bäckström, Thomas Link, Eric P. Bennet, Henrik Clausen, Thomas Noll, Gunnar C. Hansson, Joy Burchell et al. · 2005 · The Journal of Immunology
  78. The Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance
    Nona Janikashvili, Bernard Bonnotte, Emmanuel Katsanis, Nicolas Larmonier · 2011 · Clinical and Developmental Immunology
  79. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma
    Wei-Shu Wang, Po‐Min Chen, Huann-Sheng Wang, Wen-Yih Liang, Yeu Su · 2006 · Carcinogenesis
  80. Photodynamic therapy-generated vaccines: relevance of tumour cell death expression
    Mladen Korbelik, Brandon Stott, Jinghai Sun · 2007 · British Journal of Cancer
  81. A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
    Rebecca Epperly, Stephen M Gottschalk, Mireya Paulina Velasquez · 2020 · Frontiers in Oncology
  82. Ectopic Expression of Vascular Cell Adhesion Molecule-1 as a New Mechanism for Tumor Immune Evasion
    Ken-Yu Lin, Dan Lü, Chien‐Fu Hung, Shiwen Peng, Lanqing Huang, Chunfa Jie, F. Murillo, Jesse W. Rowley, Ya-Chea Tsai, Liangmei He et al. · 2007 · Cancer Research
  83. Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients
    Nicole Suciu‐Foca, Nikki M. Feirt, Qing-Yin Zhang, George Vlad, Zhuoru Liu, Hana Lin, Chih‐Chao Chang, Eric K. Ho, Adriana I. Colovai, Howard L. Kaufman et al. · 2007 · The Journal of Immunology
  84. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome
    Shoichi Hazama, Yusuke Nakamura, Hiroko Takenouchi, Nobuaki Suzuki, Ryouichi Tsunedomi, Yuka Inoue, Yoshihiro Tokuhisa, Norio Iizuka, Shigefumi Yoshino, Kazuyoshi Takeda et al. · 2014 · Journal of Translational Medicine
  85. Cytokine-driven regulation of NK cell functions in tumor immunity: Role of the MICA-NKG2D system
    Norberto W. Zwirner, Mercedes Beatriz Fuertes, Marı́a Victoria Girart, Carolina I. Domaica, Lucas Ezequiel Rossi · 2007 · Cytokine & Growth Factor Reviews
  86. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity
    Jose Alejandro Guevara-Patino · 2006 · Journal of Clinical Investigation
  87. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
    Luisa Chocarro, Miren Zuazo, Hugo Arasanz, Ana Bocanegra, Carlos Hernandez, Gonzalo Fernández, María Jesús García-Granda, Ester Blanco, Ruth Vera, Grazyna T. Kochan et al. · 2020 · Frontiers in Pharmacology
  88. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis
    Claudia Stolz, Georg Heß, Patricia S. Hähnel, Florian Grabellus, Sandra Hoffarth, Kurt Werner Schmid, Martin Schüler · 2008 · Blood
  89. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
    Takuya Osada, Sandip Pravin Patel, Scott A. Hammond, Koya Osada, Michael Andrew Morse, Herbert Kim Lyerly · 2015 · Cancer Immunology Immunotherapy
  90. Novel antibodies as anticancer agents
    Inbal Zafir‐Lavie, Y Michaeli, Yoram Reiter · 2007 · Oncogene
  91. Prostate stem cell antigen: A prospective therapeutic and diagnostic target
    Adam B. Raff, Andrew Gray, W. Martin Kast · 2008 · Cancer Letters
  92. HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation
    Josefa Antonia Rodrı́guez · 2017 · Oncology Letters
  93. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
    Agnete S. T. Engelsen, Maria Lie Lotsberg, Raefa Abou Khouzam, Jean Paul Thiery, James B. Lorens, Salem Chouaı̈b, Stéphane Terry · 2022 · Frontiers in Immunology
  94. Mathematical model of tumor–immune surveillance
    Khaphetsi Joseph Mahasa, Rachid Ouifki, Amina Eladdadi, Lisette G. de Pillis · 2016 · Journal of Theoretical Biology
  95. Colon cancer and the immune system: The role of tumor invading T cells
    Maximilian J. Waldner · 2006 · World Journal of Gastroenterology
  96. Immunization Delivered by Lentiviral Vectors for Cancer and Infectious Diseases
    Bi-Liang Hu, April Tai, Pin Wang · 2011 · Immunological Reviews
  97. Potent Selection of Antigen Loss Variants of B16 Melanoma following Inflammatory Killing of MelanocytesIn vivo
    Luis A Sanchez-Perez, Timothy J. Kottke, Rosa María Díaz, Atique U. Ahmed, Jill Thompson, Heung Chong, Alan A. Melcher, Sheri L. Holmen, Gregory A. Daniels, Richard G. Vile · 2005 · Cancer Research
  98. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer
    Toru Masuzawa, Yoshiyuki Fujiwara, Kaoru Okada, AYUMU NAKAMURA, Shuji Takiguchi, Kiyokazu Nakajima, Hiroshi Miyata, Makoto Yamasaki, Yukinori Kurokawa, Ryuji Osawa et al. · 2012 · International Journal of Oncology
  99. Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study
    Marlies S. Reimers, Charla C. Engels, Hein Putter, Hans Morreau, Gerrit‐Jan Liefers, Cornelis JH van de Velde, Peter J.K. Kuppen · 2014 · BMC Cancer
  100. Vaccination for Treatment and Prevention of Cancer in Animal Models
    Federica Cavallo, Rienk Offringa, Sjoerd H. van der Burg, Guido Forni, Cornelis J.M. Melief · 2006 · Advances in immunology